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Porphyria5-Aminolevulinate synthase (ALAS) catalyzes the initial step of mammalian heme biosynthesis, the
condensation between glycine and succinyl-CoA to produce CoA, CO2, and 5-aminolevulinate. The
crystal structure of Rhodobacter capsulatus ALAS indicates that the adenosyl moiety of succinyl-
CoA is positioned in a mainly hydrophobic pocket, where the ribose group forms a putative hydro-
gen bond with Lys156. Loss-of-function mutations in the analogous lysine of human erythroid ALAS
(ALAS2) cause X-linked sideroblastic anemia. To characterize the contribution of this residue toward
catalysis, the equivalent lysine in murine ALAS2 was substituted with valine, eliminating the possi-
bility of a hydrogen bond. The K221V substitution produced a 23-fold increase in the KSCoAm and a 97%
decrease in kcat=K
SCoA
m . This reduction in the specificity constant does not stem from lower affinity
toward succinyl-CoA, since the KSCoAd of K221V is lower than that of wild-type ALAS. For both
enzymes, the KSCoAd value is significantly different from the K
SCoA
m . That K221V has stronger binding
affinity for succinyl-CoA was further deduced from substrate protection studies, as K221V achieved
maximal protection at lower succinyl-CoA concentration than wild-type ALAS. Moreover, it is the
CoA, rather than the succinyl moiety, that facilitates binding of succinyl-CoA to wild-type ALAS, as
evident from identical KSCoAd and K
CoA
d values. Transient kinetic analyses of the K221V-catalyzed reac-
tion revealed that the mutation reduced the rates of quinonoid intermediate II formation and decay.
Altogether, the results imply that the adenosyl-binding site Lys221 contributes to binding and
orientation of succinyl-CoA for effective catalysis.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
5-Aminolevulinate (ALA) represents the first committed precur-
sor of heme biosynthesis that is produced by all heme-synthesizing
organisms [1]. In non-plant eukaryotes and certain bacteria, ALA
[with coenzymeA (CoA) and CO2 as byproducts] is synthesized
from glycine and succinyl-CoA, during a condensation reaction
catalyzed by the pyridoxal 50-phosphate (PLP)-dependent enzyme,
5-aminolevulinate synthase (ALAS) [1,2]. Disturbances in the rate
of ALA biosynthesis due to loss-of-function and gain-of-functionmutations in the erythroid-specific ALAS gene (ALAS2) result in
the erythropoietic disorders X-linked sideroblastic anemia (XLSA)
and X-linked protoporphyria (XLPP), respectively [3–5].
The complex, multi-intermediate reaction cycle of ALAS, which
has been a subject of extensive experimental studies [6–13], is out-
lined in Scheme 1. In the absence of substrates, PLP is covalently
attached to an active site lysine (Lys313 of murine ALAS2 [abbrevi-
ated as mALAS2]) forming what is commonly referred as an inter-
nal aldimine (Scheme 1, I) [14,15]. Transaldimination occurs upon
the entry of glycine, during which the internal aldimine is
displaced and an external aldimine adduct is formed between
PLP and the amino acid substrate (Scheme 1, II) [6,8]. Subsequent
removal of the pro-R proton of glycine generates an initial, reso-
nance stabilized, quinonoid intermediate (Scheme 1, III) that acts
as a nucleophile in the condensation with succinyl-CoA [11–13].
During this process, CoA is released, and decarboxylation of the
resulting 2-amino-3-ketoadipate intermediate (Scheme 1, V),
yields a second quinonoid intermediate [referred to as quinonoid
Scheme 1. Proposed chemical mechanism of mALAS2. (I) Internal aldimine complex, (II) glycine-external aldimine, (III) quinonoid intermediate I, (IV) glycine–succinyl-CoA
condensation intermediate, (V) 2-amino-3-ketoadipate intermediate, (VI) enol intermediate, (VII) quinonoid intermediate II, (VIII) ALA-external aldimine. This scheme was
originally published in Ref. [12] in the Journal of Biological Chemistry.  The American Society for Biochemistry and Molecular Biology.
Fig. 1. Lys156 (gray) of R. capsulatus ALAS coordinates the positioning of the
adenosyl group of succinyl-CoA (magenta). On opposite sides of Lys156 are b-strand
134–138 and a-helix 143–150 (cyan), which are connected by a linker that contains
the catalytic His142. R. capsulatus ALAS Lys156 and His142 correspond to Lys221
and His207 in mALAS2. Image created with Pymol using PDB: 2BWO.
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equilibrium with an enol (Scheme 1, VI) [6–8,12]. The release of
ALA from the active site, guided by conformational transitions,
represents the last, and rate-limiting, step of the reaction [6–8].
ALAS is a homodimeric enzyme whose individual active sites
are located at the dimeric interface and are composed of amino
acids from each subunit [16,17]. The internal aldimine adduct
resides deep in the active site interior, where glycine also binds
upon its entry [17]. Crystallographic data indicate that association
of succinyl-CoA with Rhodobacter capsulatus ALAS entails interac-
tions with amino acids from the N-terminal, catalytic, and
C-terminal domains of one monomer and the catalytic domain
from the opposite monomer [17]. These extensive interactions
ensure optimal positioning between the carbonyl group of the
succinyl-moiety and the Ca of glycine, which is necessary for effec-
tive condensation of the substrates during catalysis. The adenosyl
group of succinyl-CoA is important for initial recognition and is
positioned within a mainly hydrophobic pocket, located on the
active site surface [17]. Lys156 (R. capsulatus ALAS numbering;
Lys221 in mALAS2) outlines the surface of this pocket, and its side
chain associates with the ribose group through a putative hydro-
gen bond (Fig. 1) [17]. Mutations in the analogous lysine of human
ALAS2 have been reported in cases of pyridoxine-responsive XLSA,
implicating that this amino acid has an important physiological
role in catalysis [18]. However, in the absence of a crystallographic
structure of the reported XLSA variant, [i.e., K299Q [18] (human
ALAS numbering; Lys221 in mature mALAS2)] and detailed kinetic
studies, a potential hydrogen bond between the Gln side chain and
the ribose group cannot be ruled out and the effects of the
mutation in the positioning of the succinyl-CoA substrate withinthe active site and catalysis are difficult to predict. The pantetheine
moiety of succinyl-CoA occupies a narrow channel that connects
the surface of the active site to the interior, while the positioning
of the succinyl moiety is coordinated by amino acids from the
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interaction stabilizes the closed conformation of ALAS by reducing
the segmental motions of the active site loop. Furthermore, it is
clear from the crystal structure of ALAS [17] that the association
of succinyl-CoA with the enzyme profoundly minimizes the expo-
sure of the active site interior to the solvent, partly due to stabiliza-
tion of the closed conformation and occupancy of the narrow
channel by the pantetheine moiety. However, at present, it is not
known how catalysis might be influenced by reducing the expo-
sure of the active site to the solvent.
The elucidation of the crystal structure of ALAS in complex with
succinyl-CoA was followed by several studies that investigated the
catalytic role of active site amino acids that coordinate the posi-
tioning of the succinyl-moiety [11,12,19], while largely ignoring
those that associate with the adenosyl group, even though substi-
tutions in this region can cause XLSA [18]. In this study, we charac-
terized the catalytic role of Lys221 from the adenosyl-binding
pocket of mALAS2 by disrupting the putative hydrogen bond that
its side chain forms with the ribose moiety through substitution
with the hydrophobic amino acid valine. Our study reveals that
K221V increases KSCoAm by 23-fold, and that this increase does not
originate from weaker binding affinity, but instead from effects
of the mutation on individual catalytic rates, including that of qui-
nonoid intermediate II formation and decay. Moreover, significant
differences between KSCoAd and K
SCoA
m were detected, implicating
that the latter constant should not be used as a measure of binding
affinity. Furthermore, we discerned that binding of succinyl-CoA to
wild-type mALAS2 is primarily facilitated by the CoA moiety, and
that Lys221 contributes toward the recognition of CoA.2. Materials and methods
2.1. Reagents
The following reagents were obtained from Fisher Scientific:
glycine, potassium phosphate monobasic, potassium phosphate
dibasic, HEPES, and glycerol. A bicinchoninic acid assay kit was
from Thermo Scientific. Pyridoxal 50-phosphate, bovine serum
albumin (BSA) standards, DEAE resin, ACA-44 ultrogel, and sodium
cyanoborohydride were from Sigma–Aldrich.
2.2. Construction and isolation of the K221V variant
The K221V variant was obtained by screening a library of
mALAS2 variants for ALAS activity, as described previously for
the T148A variant [12].
2.3. Overproduction, purification, and determination of protein
concentrations
Wild-type mALAS2 and the K221V variant were overproduced
and purified as described elsewhere [20]. SDS–PAGE analyses cor-
roborated that the eluted proteins were purified to homogeneity.
The protein concentration used for steady-state kinetic measure-
ments was quantified using the bicinchoninic acid (BCA) assay,
according to a protocol provided by the manufacturer (Thermo Sci-
entificTM PierceTM) that entails incubation of the proteins of interest
and BSA standards for 30 min at 37 C upon the addition of the
working reagent. The concentration of the enzymes used for tran-
sient kinetic measurements was determined spectroscopically [21].
2.4. Steady-state kinetics
A continuous spectrophotometric assay [22] was used to deter-
mine the steady-state kinetic activities of wild-type mALAS2 andK221V enzyme variant. ALAS activity was measured at pH 7.5
and 37 C using a Shimadzu UV-2401 PC spectrophotometer. The
final concentration of enzyme was 2 lM (wild-type mALAS2 or
K221V), while the concentration of substrates ranged from
(0.25–10)Km. All reactions were performed in a buffer composed
of 20 mM HEPES, pH 7.5, and 10% glycerol. Secondary plots of
apparent Vmax as a function of substrate concentration were
constructed and the steady-state kinetic parameters were obtained
from fitting the data to the Michaelis–Menten equation using
non-linear regression analyses (SigmaPlot software).
2.5. Equilibrium dissociation constants for succinyl-CoA and CoA
The equilibrium dissociation constants (Kd) for succinyl-CoA
and CoA were determined at 37 C and pH 7.5 by measuring
the quenching of intrinsic protein fluorescence at 340 nm
(kex = 280 nm) upon titration of the enzyme (wild-type mALAS2
or K221V) with increasing concentration of ligand (succinyl-CoA
or CoA). Titrations were performed by adding small aliquots of
increasing concentrations of succinyl-CoA or CoA (from a 24 mM
stock) to a reaction containing 1 lM enzyme (wild-type mALAS2
or K221V) in a buffer composed of 20 mM HEPES, pH 7.5, and
10% glycerol while stirring (the buffer pH did not change upon
addition of ligands). Following incubation period of 1 min at
37 C, spectra were collected using a Shimadzu RF5301 PC spec-
trofluorophotometer. Ligand addition did not significantly alter
the final volume of the reaction (4% change in the final volume).
The fraction of ligand bound (F.B) to the enzyme was obtained by
normalizing the data using Eq. (1),
F:B: ¼ x xi
xf  xi ð1Þ
where x represents the maximal fluorescence emission at specific
ligand concentration, xi is the emission in the absence of ligands,
and xf is the emission at the highest concentration of ligand when
the enzyme was fully saturated. The equilibrium dissociation
constant, Kd, was determined by fitting the data to Eq. (2), using
SigmaPlot software for the non-linear regression analyses
Y ¼ Ymax½S
Kd þ ½S : ð2Þ2.6. Stopped-flow absorption spectroscopy experiments
A KinTek stopped-flow apparatus (model SF-2001) was used to
monitor transient changes in absorbance at a single wavelength
(either 420 or 510 nm) upon rapid mixing of enzyme and reactants.
Prior to the kinetic measurements, the purified, concentrated pro-
teins were dialyzed into a 50 mM phosphate, pH 7.5, buffer with
10% glycerol (v/v) and 40 lM PLP. All reactions were performed
at 18 C in a buffer composed of 50 mM phosphate, pH 7.5,
(37 mM K2HPO4/13 mM KH2PO4) and 10% glycerol (v/v). Reactions
under single turnover conditions, with enzyme molar concentra-
tion in excess over succinyl-CoA, were monitored by following
the changes in absorbance at 510 nm. One of the syringes con-
tained 120 lM enzyme (either wild-type mALAS2 or K221V) and
200 mM glycine in the above buffer, while the other syringe con-
tained 40 lM succinyl-CoA in the same buffer. The formation of
the external aldimine, under multiple turnover conditions, was
monitored at 420 nm; one of the syringes contained 60 lM
enzyme (wild-type mALAS2 or K221V) and buffer, and the other
syringe 200 mM glycine in the same buffer. Reductions of the
internal aldimine with sodium cyanoborohydride were monitored
at 420 nm. One of the syringes contained 40 lM enzyme (wild-
type mALAS2 or K221V) in phosphate buffer, with succinyl-CoA
concentrations ranging from 0 to 2.5 mM, while 5 mM sodium
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other syringe. The concentration of reactants in the observation
chamber of all stopped-flow experiments reported in this study
is one-half of that present in the syringes. The progress curves of
the reactions were described using an equation with either one
or three exponentials:
At ¼
X3
n¼1
aiekit þ c ð3Þ
where At is the absorbance at time t, a is the amplitude of each
phase, k is the observed rate constant for each phase and c is the
final absorbance. For the sodium cyanoborohydride substrate
protection experiments, in order to determine the concentration
of succinyl-CoA at which one-half of the maximal protection is
achieved, the reduction rates were normalized using Eq. (1), where
x represents the rate at a given succinyl-CoA concentration, xi is the
rate in the absence of succinyl-CoA, and xf is the rate at the highest
concentration of substrate when a plateau was reached. The data
were fitted to Eq. (4) using non-linear regression analysis (Sigma-
Plot) to obtain the constant (K0) that signifies the succinyl-CoA con-
centration when the protection against reduction is 1/2the maximal
A ¼ Amax½S
K 0 þ ½S : ð4Þ3. Results
3.1. Screening and selection of the K221V variant
A combinatorial active-site saturation test (CAST) [23] library of
mALAS2 variants, in which random mutations were introduced
simultaneously in the adenosyl-binding site, specifically at posi-
tions 214 and 221, was screened for functional ALAS variants using
the ALA auxotrophic strain of HemA Escherichia coli HU227 cells
[24]. Permissible substitutions at position 221, which is occupied
by Lys in wild-type mALAS2, included Ala, Arg, Asn, His, Ile, Leu,
Ser, Thr and Val (data not shown). Cys, Phe, Pro and Tyr were also
tolerated substitutions provided that wild-type mALAS2 I214 was
simultaneously mutated (data not shown). Since our objective in
examining the catalytic role of K221 was to eliminate the putative
hydrogen bond between its side chain and the ribose group of the
succinyl-CoA adenylate, we focused on the characterization of
K221V in relation to wild-type mALAS2.
3.2. Steady-state kinetics
The steady-state kinetic parameters and specificity constants
for wild-type mALAS2 and the K221V variant, determined at pH
7.5 and 37 C, are reported in Table 1. In comparison to the wild-
type enzyme, the kcat value for the K221V variant was moderately
reduced. However, relative to the wild-type enzyme, the K221V
mutation resulted in a 23-fold increase in the KSCoAm value and
97% reduction in kcat=K
SCoA
m . Interestingly, even though Lys221 does
not participate in the binding of glycine, a 6-fold increase in the
KGlym was also detected for the K221V variant.
3.3. Equilibrium dissociation constants (Kd) for succinyl-CoA and CoA
The Kd values for succinyl-CoA and CoA were obtained by mon-
itoring the quenching of the intrinsic protein fluorescence (pH 7.5
and 37 C) that resulted upon titration of the enzyme (wild-type
mALAS2 or K221V) with increasing concentration of ligand (Fig. 2
and Table 2). Our data reveal that the binding of succinyl-CoA to
the wild-type enzyme is primarily facilitated by the CoA, and notthe succinyl moiety, since the Kd values for succinyl-CoA and CoA
are comparable within error (Table 2). Interestingly, in comparison
to the wild-type enzyme, the K221V mutation lowered the KSCoAd by
25%, indicating stronger affinity of the variant toward succinyl-
CoA. However, the binding of CoA to the variant enzyme is weak-
ened by the mutation, as evident from the increased KCoAd . This
implies an important role for the succinyl-moiety in the binding
of succinyl-CoA to the active site of the K221V enzyme. Impor-
tantly, for either enzyme, there are significant differences between
the KSCoAm and K
SCoA
d [Tables 1 and 2; (see Section 4)].
3.4. Single turnover reactions: quinonoid intermediate II formation
The pre-steady-state rates for quinonoid intermediate II forma-
tion [kmax = 510 nm (Scheme 1, VII)] resulting from the reaction
between the enzyme (wild-type or K221V)-glycine complex and
succinyl-CoA were determined during a single turnover, with the
enzymemolar concentration in excess over succinyl-CoA. The reac-
tions were conducted at pH 7.5 and 18 C, rather than 37 C,
because at the higher temperature, it was challenging to character-
ize the individual kinetic phases associated with the transient for-
mation and decay of the quinonoid intermediate II. As presented in
Fig. 3, the reactions for either the wild-type or variant enzyme are
best described by an equation with three exponentials. Previous
studies with mALAS2 led to the assignment of the three kinetic
phases to: (k1) formation of the quinonoid intermediate II upon
decarboxylation of the 2-amino-3-ketoadipate intermediate
[Scheme 1, V], (k2) decay of the quinonoid intermediate II due to
protonation of the enol [Scheme 1, VI], and (k3) release of ALA from
the active site, guided by conformational transitions [7]. Even
though Lys221 is located on the surface of the active site [17],
and, consequently, does not directly act as an acid-base catalyst
during the formation or decay of the quinonoid intermediate II,
its substitution with a valine resulted in a decrease in the rates
(Table 3). Specifically, relative to the wild-type reaction, the
K221V variant catalyzes formation of the quinonoid intermediate
II with a rate that is decreased by 29% (k1 = 2.7 ± 0.02 s1 vs.
k1 = 3.8 ± 0.03 s1), while decreases of 39% and 21% were detected
for k2 and k3, respectively (Table 3).
3.5. Multiple turnover reactions: glycine-associated external aldimine
formation
The reaction between the enzyme (wild-type mALAS2 or
K221V) and glycine was examined by monitoring the changes in
absorbance at 420 nm (at pH 7.5 and 18 C) associated with the
formation of the external aldimine complex (Scheme 1, II). Because
of the high Km for glycine (Table 1), we had to resort to examining
the reaction under multiple, rather than single, turnover condi-
tions. Monophasic processes best describe the kinetic traces pro-
duced by the reactions of glycine with either the wild-type or
variant enzymes (Fig. 4). Importantly, the K221V mutation has
no pronounced effect on this transaldimination reaction, yielding
an observed rate constant, k1 = 0.09 ± 0.001 s1, which is nearly
indistinguishable from the rate for the wild-type reaction
(k1 = 0.08 ± 0.001 s1).
3.6. Substrate protection studies: reduction with sodium
cyanoborohydride
Since succinyl-CoA binds on the enzymatic surface and mini-
mizes the exposure of the active site to the solvent, while the inter-
nal aldimine adduct (PLP-Lys313; mALAS2 numbering [Scheme 1,
I]) is positioned deep within the active site interior [17], the rate
of reduction of the internal aldimine with imine-specific reducing
Fig. 2. Binding isotherms resulting from the titration of wild-type mALAS2 (A) and K221V (B) with increasing concentrations of succinyl-CoA, and from the titration of wild-
type mALAS2 (C) and K221V (D) with increasing concentrations of CoA. All reactions were done in duplicates.
Table 1
Steady-state kinetic parameters and specificity constants.
Enzyme kcat (s1) K
Gly
m (mM) K
SCoA
m (lM) kcat=K
Gly
m (s
1 M1) kcat=KSCoAm (s
1 M1)
wt mALAS2 0.25 ± 0.004 8 ± 0.7 1.0 ± 0.1 31.2 ± 3.0 2.5  105 ± 0.3  105
K221V 0.17 ± 0.002 50 ± 13 23 ± 2 3.4 ± 0.7 0.07  105 ± 0.007  105
Table 2
Equilibrium dissociation constants for succinyl-CoA and CoA.
Enzyme KSCoAd (lM) K
CoA
d (lM)
wt mALAS2 297 ± 7 302 ± 12
K221V 223 ± 8 431 ± 17
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with ALAS. Thus, we performed substrate protection studies with
succinyl-CoA by monitoring the transient decrease in absorbance
at 420 nm upon reaction with sodium cyanoborohydride (a selec-
tive imine reducing agent under physiological conditions) [25].
The kinetic traces that resulted from reduction of the wild-type
mALAS2 or K221V internal aldimine adducts, either in the presence
or absence of succinyl-CoA, are best-described by a single-
exponential equation (Fig. 5A and B). Upon increase in the concen-
tration of succinyl-CoA, for either enzyme,we detected a decrease in
the rate of internal aldimine reduction until a plateau was reached,
and by fitting the normalized rates to an equation for a hyperbola(Fig. 5C and D), we obtained the concentration of succinyl-CoA at
which one-half of the maximal protection against reduction is
observed (K0). The data reveal that with K221V, maximal protection
is reached at a lower succinyl-CoA concentration (K0 = 136 ± 11 lM)
relative to wild-type mALAS2 (K0 = 261 ± 75 lM).
4. Discussion
The elucidation of the crystal structure of R. capsulatus ALAS in
complex with succinyl-CoA contributed to identification of the
amino acids implicated in coordination of this substrate within
the enzymatic active site [17]. Thus far, however, kinetic and
mechanistic studies have been directed toward understanding
the catalytic role of active site amino acids that coordinate the
positioning of the succinyl-moiety of succinyl-CoA [11,12,19],
while the catalytic importance of residues that are involved in
the recognition of the adenosyl moiety has never been appraised
and characterized. In this study, we performed detailed steady
and pre-steady state kinetic analyses in order to understand the
Fig. 3. Progress curves for the single turnover reactions between (A) wild-type
mALAS2-glycine complex or (B) K221V-glycine complex and succinyl-CoA moni-
tored at 510 nm. The kinetic traces (data points in purple), collected at pH 7.5 and
18 C, were fitted to a three-exponential equation, and the fitted lines are shown in
black.
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located on the surface of the mainly hydrophobic, adenosyl-
binding pocket of ALAS, forms a hydrogen bond with the ribose
group of succinyl-CoA (Fig. 1), and its physiological significance
for effective catalysis is evident from reports that substitutions at
this position lead to the erythropoietic disorder XLSA [18].
When the hydrogen bond between the side chain of Lys221 and
the adenosyl moiety of succinyl-CoA was disrupted by introducing
a valine, we observed that the mutation had only a moderate effect
on the catalytic turnover of mALAS2, resulting in a 32% reduction in
the kcat value (Table 1).While researchers have identified numerous
XLSA-associated mutations in the human ALAS2 (hALAS2) gene [3],
apart from a recent study reporting Vmax values for two XLSA
hALAS2 variants, inwhich themutations perturbed protein–protein
interactions without impacting the catalytic activity [26], informa-
tion is lacking on how themajority of XLSAmutations affect the cat-
alytic turnover (kcat) of hALAS2. Evenwhen the catalytic activities ofTable 3
Observed rate constants for the reaction between the enzyme–glycine complex and
succinyl-CoA.
Enzyme k1a (s1) k2b (s1) k3c (s1)
wt mALAS2 3.8 ± 0.03 0.59 ± 0.005 0.038 ± 0.001
K221V 2.7 ± 0.02 0.36 ± 0.003 0.030 ± 0.001
a Rate for quinonoid intermediate II formation.
b Rate for first step of quinonoid intermediate II decay.
c Rate for second step of quinonoid intermediate II decay.the XLSA variants were estimated [18,27–30], their measurements
were limited to initial reaction velocities and, often, involved the
use of cell lysates or ALAS fusion proteins [18,27–30]. Therefore,
at present, it is not known the extent of decrease or the lower limit
in the kcat value of ALAS2 associatedwith themanifestation of XLSA.
Despite the mild effects of the K221V mutation on the catalytic
turnover of mALAS2, the K221V mutation has a profound effect
on the specificity constant for succinyl-CoA, with a 97% decrease
in the kcat=K
SCoA
m value of the K221V variant relative to that of the
wild-type enzyme (Table 1). This reduction in the specificity con-
stant, which is due to a 23-fold increase in KSCoAm , does not stem from
weakened affinity of the variant toward succinyl-CoA, since con-
trary to expectations, the KSCoAd value for the K221V variant is actu-
ally lower than the one for the wild-type enzyme, implicating
tighter binding (Table 2).
Even for a simple catalytic mechanism that consists of a single
reaction intermediate, the Michaelis constant, Km, which is indica-
tive of the substrate concentration when v = 1/2 Vmax, is a complex
function consisting of multiple rates [31], and thus, it should not be
misinterpreted with the equilibrium dissociation constant (Kd),
because the two will only be identical when k1 is significantly
greater than kcat. In the case of mALAS2, comparison between
KSCoAm and K
SCoA
d reveals significant differences between the two
constants. Specifically, for the wild-type enzyme, the dissociation
constant is 300-fold greater than the Michaelis constant, while
for the K221V variant, the ratio between these two constants isFig. 4. Progress curves for the multi-turnover reactions between (A) wild-type
mALAS2 or (B) K221V and glycine monitored at 420 nm. The kinetic traces (data
points in purple), collected at pH 7.5 and 18 C, are best described by an equation
with one exponential, and the fitted lines are shown in black.
Fig. 5. Selected kinetic traces for the sodium cyanoborohydride reductions of the (A) wild type mALAS2 and (B) K221V internal aldimine adducts monitored at 420 nm.
Monophasic processes best described the kinetic traces in the absence (purple) or presence of 1.25 mM succinyl-CoA (gray) and the fitted lines are shown in black. The rates
were normalized as described in Section 2, and K0 = 261 ± 75 lM and K0 = 136 ± 11 lMwere obtained by fitting the normalized rates for wild-type mALAS2 (C) and the K221V
enzyme (D) to Eq. (4), respectively. For the succinyl-CoA concentrations reported in (C) and (D), each symbol represents the average of three reaction rates and the error bars
associated with the determined maximal protection values are obscured by the symbols.
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KSCoAm does not originate from weakened affinity of the K221V vari-
ant toward succinyl-CoA, but rather from effects of the mutation
on specific catalytic rate(s). Given the role of Lys221 in coordinat-
ing the positioning of succinyl-CoA [17], it is possible that the
mutation affects the rate of condensation between the substrates,
probably by impairing the attainment of a catalytically competent
orientation between glycine and succinyl-CoA. However, presently,
there is no assay that would allow us to measure the condensation
rates and examine the validity of this hypothesis.
One of the reaction rates that we do know to be perturbed by
the K221V mutation is that of quinonoid intermediate II catalysis
(Table 3). Our single turnover transient kinetic studies revealed
that the K221V variant catalyzes the formation and decay of the
quinonoid intermediate II with rates that are reduced by about
one-third relative to the wild-type reaction. This finding is rather
intriguing, particularly since Lys221 is located on the enzymatic
surface, far from any catalytic center [17], and is not directly
involved in acid-base catalysis. The most probable explanation
for this detrimental effect is that the mutation results in subtle
structural perturbations of the active site, leading to an increase
in the energetic barrier required for quinonoid intermediate II
catalysis. The analogous lysine (Lys156) in R. capsulatus ALAS
occupies a strand (b 156–159; R. capsulatus ALAS numbering) in
the catalytic domain that is part of a mostly parallel, seven
stranded b-sheet, covered on either side by nine helices [17]. Onopposite sides of Lys156 are b-strand 134–138 and a-helix
143–150 (Fig. 1), which are connected by a linker that contains
His142—the amino acid postulated to act as an acid catalyst during
the formation of the quinonoid intermediate II [7]. Thus, it is pos-
sible that structural perturbations introduced by the K221V muta-
tion indirectly affect the optimal positioning of the catalytic
histidine.
Our data also indicate that the binding of succinyl-CoA to the
active site of mALAS2 is primarily facilitated by the CoA, rather
than the succinyl moiety, as evident from the identical Kd values
for the two ligands (Table 2). Moreover, from the increase in KCoAd
that was detected for the K221V variant (Table 2), it can be
deduced that Lys221 is important for initial recognition of the
CoA moiety. Intriguingly, even though the K221V variant displays
weaker binding toward CoA, its affinity for succinyl-CoA is actually
higher than that of wild-type mALAS2 (Table 2), implicating that
through stronger interactions with the succinyl moiety, the active
site of the variant appears to compensate for its reduction in the
affinity toward CoA.
The crystal structure of R. capsulatus ALAS [17] indicates that
association of succinyl-CoA with the enzyme leads to significant
reduction in the exposure of the active site to the solvent. This
minimized exposure is due to stabilization of the closed conforma-
tion and occupancy of the active site channel by the pantetheine
moiety. In order to validate the crystallographic predictions
experimentally, we performed substrate protection studies with
B.M. Stojanovski, G.C. Ferreira / FEBS Open Bio 5 (2015) 824–831 831succinyl-CoA by monitoring the reduction of the internal aldimine,
which is located in the active site interior [17], and the results
revealed that succinyl-CoA binding does indeed minimize the
exposure of the active site interior to the solvent (Fig. 5). These
studies also indicate that with K221V, maximal level of protection
is achieved at lower concentrations of succinyl-CoA relative to
wild-type mALAS2, which is consistent with the finding that the
variant has a lower KSCoAd than the wild-type enzyme.
In summary, the data presented in this study reveal that the
K221V mutation reduces the specificity constant for succinyl-
CoA, and that the increase in KSCoAm does not originate from weaker
binding affinity, but rather from impairments in individual cat-
alytic rates, including that of quinonoid intermediate II catalysis.
Furthermore, it is possible that in vivo, substitutions at position
Lys221 might have more pronounced effect on ALA biosynthesis,
particularly if this lysine participates in protein–protein interac-
tions with the b-subunit of ATP-specific succinyl-CoA synthetase
(SUCLA2), the protein that is believed to channel succinyl-CoA to
the active site of ALAS [32]. In fact, impairment in the ability to
interact with the b-subunit of ATP-specific succinyl-CoA syn-
thetase was detected in several ALAS2 variants associated with
XLSA [26,32]. Thus, future endeavors should be directed toward
detailed understanding of the structural regions of ALAS that are
necessary for these protein–protein interaction.
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